A miniature biosensor and monitoring method for continuous analyte monitoring
By setting shallow and deep electrodes at different depths in the micro biosensor, the problem of sensor detection performance fluctuating over time was solved, and stable signal output was achieved throughout the entire cycle.
Patent Information
- Application Number
- CN202611373334.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-04
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2046-09-04
AI Technical Summary
Existing analyte sensors exhibit significant fluctuations in detection performance over time after implantation, making accurate monitoring throughout the entire lifecycle impossible.
Design a miniature biosensor comprising a shallow electrode and a deep electrode. The shallow electrode is closer to the connection point, while the deep electrode is closer to the distal end of the implantation site. The two electrodes are located at different depths under the host skin. The concentration of the analyte is obtained at different time periods through the shallow and deep sensing layers.
This achieves enhanced signal stability throughout the entire wearing cycle. The shallow electrode provides accurate signals in the early stages of implantation, while the deep electrode maintains signal output in the later stages, ensuring that the sensor has its advantages at different stages and achieving stable monitoring.
Smart Images

Figure CN122848775B_ABST
Abstract
Description
Technical Field
[0001] This application belongs to the field of medical device technology, specifically relating to a miniature biosensor and monitoring method for continuous analyte monitoring. Background Technology
[0002] Monitoring various physiological data within an individual is crucial for assessing their health. Deviations from normal physiological data levels often indicate underlying physiological conditions, such as metabolic status or disease. In most scenarios, subcutaneous, interstitial, and skin analyte sensors can reduce discomfort while ensuring measurement accuracy. Continuous analyte monitoring devices employing implantable physiological monitoring sensors are the preferred solution for achieving continuous monitoring of physiological indicators. These sensors typically contain a slender implantation site whose surface biosensing layer reacts with the interstitial fluid of the subcutaneous tissue, generating and transmitting electrical signals related to analyte concentration.
[0003] However, the sensor's detection performance changes over time after implantation. Specifically, in the initial implantation phase, local bleeding and tissue inflammation caused by the puncture trauma are most severe. Electrodes located deeper in the body are more susceptible to bleeding interference due to their proximity to damaged blood vessels, resulting in poor signal accuracy. Electrodes located superficially, being farther from deep bleeding sources, are less affected by bleeding interference and have relatively accurate signals. As the wearing time increases, the healing response and foreign body reaction of superficial tissues gradually intensify. Fibroblasts migrate downwards along the sensor surface, forming fibrous encapsulation. Electrodes located superficially, being closer to the skin surface, are encapsulated first, and their signals gradually attenuate. Electrodes located deeper, being farther from the active healing response area, undergo a slower encapsulation process and maintain good signal strength.
[0004] Therefore, how to maintain high sensitivity of the analyte sensor throughout the entire wearing period to output a stable detection signal is a problem that urgently needs to be solved in this field. Summary of the Invention
[0005] This application provides a miniature biosensor and monitoring method for continuous analyte monitoring, which solves the problem that the sensitivity and accuracy of analyte sensors fluctuate greatly over time, making it impossible to achieve accurate monitoring throughout the entire wearing cycle.
[0006] The technical solution adopted in this application is as follows: A micro biosensor for continuous analyte monitoring includes a substrate with a connector and an implantation portion. The connector is located outside the host body and configured to connect to an electronic module. The implantation portion is connected to the connector and has an implantation segment configured to be implanted under the skin of the host to obtain analyte parameters. A shallow electrode is disposed in the implantation portion, and a shallow sensing layer is disposed on the surface of the shallow electrode, covering at least a portion of the shallow electrode. A deep electrode is disposed in the implantation portion, and a deep sensing layer is disposed on the surface of the deep electrode, covering at least a portion of the deep electrode. In the extension direction of the implantation portion, the length of the implantation segment is 5.5 mm to 7.5 mm, and the shallow electrode is closer to the connector than the deep electrode.
[0007] The sensor is used to be mounted to the transmitting unit, which has a bottom surface. The implantation segment extends from the bottom surface and is implanted into the host subcutaneous tissue to obtain analyte parameters. In the extension direction of the implantation segment, the shallow sensing layer has a first upper edge near the connecting portion. The distance between the first upper edge and the bottom surface is d1, where d1 is 1.6 mm to 2.3 mm.
[0008] The sensor is used to be mounted to the transmitting unit, which has a bottom surface. The implantation segment extends from the bottom surface and is implanted into the host subcutaneous tissue to obtain analyte parameters. In the extension direction of the implantation segment, the depth sensing layer has a second upper edge near the connecting portion. The distance between the second upper edge and the bottom surface is d2, where d2 is 2.8 mm to 4.4 mm.
[0009] The implantation segment includes a receiving segment and a guide segment extending from the receiving segment. The receiving segment is closer to the connection part than the guide segment. The shallow electrode and the deep electrode are located in the receiving segment. The front view of the guide segment is trapezoidal. The trapezoid includes a lower base close to the receiving segment and an upper base away from the receiving segment. The length of the upper base is less than the length of the lower base.
[0010] The angle between the hypotenuse and the upper base of a trapezoid is 52° to 72°.
[0011] The shallow and deep electrodes are configured to: obtain the analyte concentration based on a first vital sign parameter acquired by the shallow sensing layer during a first time period after implantation; and obtain the analyte concentration based on a second vital sign parameter acquired by the deep sensing layer during a second time period after the first time period.
[0012] The superficial and deep electrodes are located on the same side of the implantation site.
[0013] A shallow electrode is placed on the first side of the implantation site, and a deep electrode is placed on the second side of the implantation site, with the first and second sides positioned opposite each other.
[0014] In the direction of extension of the implantation site, the shallow electrode and the deep electrode have an overlapping area, and the shallow sensing layer and the deep sensing layer are separated.
[0015] In the direction of implantation extension, the length of the overlapping area is less than or equal to 0.5 mm.
[0016] In the extension direction of the implantation site, the shallow electrode has a first proximal edge and a first distal edge, and the shallow sensing layer has a first upper edge near the first proximal edge and a first lower edge near the first distal edge; the distance between the first upper edge and the first proximal edge is d3, and the distance between the first lower edge and the first distal edge is d4. In the extension direction of the implantation site, the deep electrode has a second proximal edge and a second distal edge, and the deep sensing layer has a second upper edge near the second proximal edge and a second lower edge near the second distal edge; the distance between the second upper edge and the second proximal edge is d5, and the distance between the second lower edge and the second distal edge is d6, wherein d3, d4, d5, and d6 are all 0-1.5 mm.
[0017] In the extension direction of the implantation site, the deep electrode has a second distal edge away from the connector, and the distance between the second distal edge and the end of the implantation site is 0-1.2 mm.
[0018] In the direction of extension of the implantation site, the length of the superficial electrode is greater than the length of the deep electrode.
[0019] In the extension direction of the implantation site, the lengths of both the shallow and deep electrodes are set to 0.8mm-4.0mm.
[0020] In the extension direction of the implantation site, the shallow electrode has a first proximal edge close to the connector, and the deep electrode has a second distal edge away from the connector, with a distance of 1.1 mm to 4.0 mm between the first proximal edge and the second distal edge.
[0021] The shallow and deep sensing layers contain glucose oxidase and an electron mediator configured to transfer electrons generated by the reaction of glucose oxidase with the host's interstitial fluid to the shallow and deep electrodes, respectively.
[0022] The implantation site has an outer membrane assembly on its surface, which covers the shallow electrode and the deep electrode. The outer membrane assembly includes a first outer membrane and a second outer membrane disposed outside the first outer membrane. The second outer membrane contains a negatively charged polymer material.
[0023] This application also discloses a method for monitoring host vital signs parameters, using the aforementioned analyte sensor. The method includes acquiring a first vital sign parameter of the host through a shallow sensing layer; acquiring a second vital sign parameter of the host through a deep sensing layer; obtaining the host's analyte concentration based on the first vital sign parameter during a first time period after implantation; and obtaining the host's analyte concentration based on the second vital sign parameter during a second time period after the first time period. Both the first and second vital sign parameters are used to characterize the host's glucose concentration.
[0024] Due to the adoption of the above technical solution, the beneficial effects achieved by this application are as follows: This application employs two electrodes positioned at the implantation site: a superficial electrode and a deep electrode, arranged along the extension direction of the implantation site. The superficial electrode is closer to the connecting portion (located at a shallower position), while the deep electrode is closer to the distal end of the implantation site (located at a deeper position), placing the two electrodes at different depths beneath the host skin after implantation. This structure determines that each electrode possesses an advantageous time period throughout the entire wearing cycle. Because the superficial electrode is located at a shallower position, its superficial sensing layer is far from deep bleeding sources in the early stages of implantation, resulting in less signal interference and higher initial signal quality. Conversely, because the deep electrode is located at a deeper position, its deep sensing layer is far from the active healing response zone on the skin surface in the later stages of implantation, resulting in a slower fibrous encapsulation process and less signal attenuation in the later stages. This structural configuration, with the two electrodes located at different depths, provides complementary characteristics in the temporal dimension. Therefore, the superficial and deep electrodes offer the sensor two signal sources with distinct advantages at different stages, significantly enhancing signal stability throughout the entire wearing cycle and achieving stable monitoring. Attached Figure Description
[0025] The accompanying drawings, which are included to provide a further understanding of this application and form part of this application, illustrate exemplary embodiments and are used to explain this application, but do not constitute an undue limitation of this application. In the drawings: Figure 1 This is a schematic diagram of the sensor's structure from a first-view perspective. Figure 2 for Figure 1 A magnified view of area A in the middle; Figure 3 This is a schematic diagram of the second-view structure of the sensor in this application; Figure 4 This is a cross-sectional view of the sensor in this application; Figure 5 This is a schematic diagram of the substrate structure according to another embodiment of this application; Figure 6 This is a cross-sectional view of the sensor and electronic module assembled together according to this application; Figure 7 This is a cross-sectional view from another perspective of the sensor and electronic module assembled together in this application; Figure 8 This is a cross-sectional view of the sensor and puncture needle assembled together according to this application; Figure 9 for Figure 8 A magnified view of area B in the middle; Figure 10 This is a graph showing the changes in CGM concentration readings over time in the first sensing area, the second sensing area, and a single standard sensor of the sensor in this application during wear.
[0026] in: 1. Substrate; 11. Connecting part; 12. Implantation part; 121. First side; 122. Second side; 123. Receiving section; 124. Guiding section; 1241. Upper base; 1242. Lower base; 125. Base; 126. Implantation section; 13. Implantation distal end; 2 Shallow electrode; 21 Shallow sensing layer; 211 First upper edge; 212 First lower edge; 22 First proximal edge; 23 First distal edge; 24 Shallow conductive layer; 25 Shallow insulating layer; 26 Overlapping region; 3. Deep electrode; 31. Deep sensing layer; 311. Second upper edge; 312. Second lower edge; 32. Second proximal edge; 33. Second distal edge; 34. Deep conductive layer; 35. Deep insulating layer; 4 pairs of electrodes; 41 pairs of conductive electrode layers; 42 pairs of insulating electrode layers; 5. Reference electrode; 51. Reference conductive layer; 52. Reference insulating layer; 53. Reference material; 6. Transmitting unit; 61. Electronic module; 62. Housing; 63. Adhesive part; 631. Bottom surface; 7. Puncture needle; 71. Cavity; 72. Beveled surface; 721. Needle tip; 722. Beveled end. Detailed Implementation
[0027] To more clearly illustrate the overall concept of this application, a detailed explanation is provided below with reference to the accompanying drawings.
[0028] Many specific details are set forth in the following description in order to provide a full understanding of this application. However, this application may also be implemented in other ways different from those described herein. Therefore, the scope of protection of this application is not limited to the specific embodiments disclosed below.
[0029] Furthermore, it should be understood in the description of this application that the terms "top", "bottom", "inner", "outer", "axial", "radial", "circumferential", etc., indicate the orientation or positional relationship based on the orientation or positional relationship shown in the accompanying drawings, and are only for the convenience of describing this application and simplifying the description, and are not intended to indicate or imply that the device or element referred to must have a specific orientation, or be constructed and operated in a specific orientation, and therefore should not be construed as a limitation of the present invention.
[0030] In this application, unless otherwise expressly specified and limited, the terms "installation," "connection," "linking," and "fixing," etc., should be interpreted broadly. For example, they can refer to a fixed connection, a detachable connection, or an integral part; they can refer to a mechanical connection, an electrical connection, or a communication connection; they can refer to a direct connection or an indirect connection through an intermediate medium; they can refer to the internal communication of two components or the interaction between two components. Those skilled in the art can understand the specific meaning of the above terms in this invention according to the specific circumstances.
[0031] In this application, unless otherwise expressly specified and limited, the "above" or "below" of the second feature can mean that the first and second features are in direct contact, or that the first and second features are in indirect contact through an intermediate medium. In the description of this specification, references to terms such as "implementation," "example," "a particular embodiment," "example," or "specific example," etc., indicate that the specific feature, structure, material, or characteristic described in connection with that embodiment or example is included in at least one embodiment or example of this application. In this specification, the illustrative expressions of the above terms do not necessarily refer to the same embodiment or example. Furthermore, the specific features, structures, materials, or characteristics described can be combined in any suitable manner in one or more embodiments or examples.
[0032] like Figures 1 to 5 As shown, a micro biosensor for continuous analyte monitoring includes a substrate 1, which has a connection portion 11 and an implantation portion 12. The connection portion 11 is located outside the host body and configured to connect to an electronic module. The implantation portion 12 is connected to the connection portion 11 and has an implantation segment 126 configured to be implanted under the skin of the host to obtain analyte parameters. A shallow electrode 2 is disposed in the implantation portion 12, and a shallow sensing layer 21 is disposed on the surface of the shallow electrode 2, covering at least a portion of the shallow electrode 2. A deep electrode 3 is disposed in the implantation portion 12, and a deep sensing layer 31 is disposed on the surface of the deep electrode 3, covering at least a portion of the deep electrode 3. In the extending direction of the implantation portion 12, the length L of the implantation segment 126 is 5.5 mm to 7.5 mm, and the shallow electrode 2 is closer to the connection portion 11 than the deep electrode 3.
[0033] In the field of continuous glucose monitoring, sensor signal attenuation exhibits two typical stages over time, which the industry categorizes as ESA (Early Signal Attenuation) and LSA (Long-term Signal Attenuation). ESA refers to the signal decline that occurs in the early stages of sensor implantation (usually several hours to 3 days after implantation). Its main causes include: local bleeding due to puncture trauma, where red blood cells, thrombin, and proteins in the blood adhere to the surface of the sensing layer, forming a physical shielding layer that hinders glucose diffusion and interferes with electron transport on the electrode surface; acute inflammatory reactions triggered by implantation, where inflammatory cells accumulate around the implant, consuming local oxygen and releasing inflammatory factors, altering the local microenvironment of the sensing layer; and temporary disturbances in tissue fluid composition—trauma causes changes in the concentration of electrolytes and metabolites in the local tissue fluid, affecting the baseline stability of electrochemical detection. LSA refers to the gradual and persistent signal decline that occurs in the later stages of sensor implantation (usually 3-7 days after implantation). The main cause is fibrous encapsulation. Fibroblasts proliferate around the implant and secrete collagen, gradually forming a dense fibrous capsule that isolates the sensor from the surrounding tissue fluid. As the thickness and density of the capsule increase, the diffusion path of glucose molecules from the tissue fluid to the surface of the sensing layer is significantly prolonged and the diffusion rate is greatly reduced, resulting in a decrease in the glucose flux reaching the sensing layer. Consequently, the signal response amplitude continues to decay until the sensor fails.
[0034] The total length of a conventional percutaneous sensor implanted subcutaneously is typically 3mm to 5mm. When the sensing layer is positioned in the middle or distal part of the implanted segment, its effective detection depth usually does not exceed 3mm, and the sensing layer is often located within the dermis. This depth presents a high risk of bleeding in the early stages of implantation due to its proximity to the capillary network within the dermis. Furthermore, in the later stages of implantation, it faces a rapid encapsulation process due to its location within the dermis where fibroblast activity is high. In other words, sensors of conventional length are in a disadvantageous position between ESA and LSA.
[0035] This application limits the length of the implantation segment 126 to 5.5mm~7.5mm, making the portion implanted under the host skin longer than the implantation segment length of conventional sensors. This allows for greater longitudinal arrangement space for the superficial electrode 2 and deep electrode 3, while the deep electrode 3 can reach deeper into the fat layer of the subcutaneous tissue. Because the superficial electrode 2 is located superficially, it is far from deep bleeding sources in the early stages of implantation and is less affected by ESA, thus providing accurate signal output in the initial implantation phase. Although the deep electrode 3 is located deeper and may face greater bleeding interference in the early stages of implantation, the initial signal quality degradation of the deep electrode 3 does not mean that the sensor has failed entirely; the superficial electrode 2 assumes the main signal output function in the early stages of implantation. Because the deep electrode 3 is located deeper into the fat layer of the subcutaneous tissue, far from the dense fibroblast-rich dermis, the fibroblast encapsulation process is significantly delayed. This means that fibroblasts need to travel a longer distance along the implantation segment surface from the dermis to deeper layers, allowing the deep sensing layer 31 to maintain high signal integrity even in the later stages of implantation. When the signal of the superficial electrode 2 attenuates due to encapsulation in the later stages of implantation, the deep electrode 3 maintains effective detection capability due to the slower encapsulation process, taking over the signal output function of the superficial electrode 2. This allows the complementary relationship between the two in the time dimension to be fully utilized: the superficial electrode 2 provides accurate signals in the early stages of implantation, while the deep electrode 3 maintains signal output in the later stages of implantation, thus simultaneously addressing the two major bottlenecks of ESA and LSA.
[0036] Furthermore, the deeper regions of the subcutaneous tissue possess a richer network of small blood vessels and capillaries than the dermis. These vessels are the primary sites for substance exchange between tissue fluid and blood, and the concentration gradient of analytes such as glucose diffusing from capillaries to the surrounding tissue fluid is gentler and the exchange efficiency is higher in this region. This application extends the length of the implanted segment 126 to 5.5mm~7.5mm, enabling the deep sensing layer 31 of the deep electrode 3 to be anchored in a deeper region of the subcutaneous tissue, where the physiological delay between the glucose concentration and the actual concentration in the blood is shorter (compared to the superficial dermis). Simultaneously, the deeper implantation location allows for a higher analyte throughput in the tissue fluid where the deep electrode is located; for example, more glucose molecules reach the surface of the deep sensing layer 31 per unit time, resulting in a stronger electrochemical current signal with a higher signal-to-noise ratio. This leads to a better correlation between the detection results and the true blood glucose level, providing higher-quality raw data for the backend algorithm. This ensures that when the deep electrode 3 takes over the dominant output from the superficial electrode 2 in the later stages of implantation, it can provide a high-signal-to-noise ratio, low-drift, high-quality signal, guaranteeing the sensor's monitoring accuracy throughout the entire implantation cycle.
[0037] Preferably, the length L of the implanted segment is 5.8mm~7.2mm, 5.5mm~7.2mm, 5.7mm~7.5mm, 5.8mm~6.8mm, 6.0mm~6.8mm, or 6.0mm~7.0mm. More preferably, the length L of the implanted segment can be 5.5mm, 5.8mm, 6.0mm, 6.1mm, 6.3mm, 6.5mm, 6.9mm, 7.0mm, or 7.3mm.
[0038] It is understandable that, such as Figure 6 , Figure 7 As shown, the sensor is used to install onto the transmitting unit 6. The transmitting unit 6 includes a housing 62 and an electronic module 61 disposed inside the housing 62. The housing 62 is provided with an adhesive part 63, which has a bottom surface 631 (the surface facing the host skin) configured to be fixed to the host skin surface. After implantation, the bottom surface 631 adheres to the host skin surface. Figure 1 The bottom surface 631 is shown by a dashed line formed by alternating long and short lines; the connecting part 11 is disposed inside the housing 62 and connected to the electronic module 61 (physical connection and / or communication connection); a portion of the implanted part 12 extends from the bottom surface 631, and the extended portion constitutes the implanted segment 126.
[0039] Furthermore, such as Figure 1 , Figure 6 , Figure 7 As shown, the implantation part 12 has an implantation distal end 13 that is away from the connecting part 11. The implantation distal end 13 is also the end of the implantation segment 126. Therefore, the length L of the implantation segment 126 is the distance between the implantation distal end 13 and the bottom surface 631 in the extending direction of the implantation part 12.
[0040] This application arranges the superficial electrode 2 and the deep electrode 3 along the extension direction of the implantation portion 12, with the superficial electrode 2 closer to the connecting portion 11 (located in a superficial subcutaneous position after implantation) and the deep electrode 3 closer to the distal end of the implantation portion 12 (located in a deeper subcutaneous position after implantation). This arrangement places the two electrodes at different depths under the host skin after implantation. This structure determines that each electrode has an advantageous time period throughout the entire wearing cycle. Because the superficial electrode 2 is located at a superficial position, its superficial sensing layer 21 is far from deep bleeding sources in the early stages of implantation, resulting in less signal interference and higher initial signal quality. Because the deep electrode 3 is located at a deeper position, its deep sensing layer 31 is far from the active healing reaction area on the skin surface in the later stages of implantation, resulting in a slower fibrous encapsulation process and slower signal attenuation in the later stages. The structural configuration of the two electrodes at different depths gives them complementary characteristics in the time dimension. Therefore, the superficial electrode 2 and the deep electrode 3 provide the sensor with two signal sources, each with its own advantages at different stages, greatly enhancing signal stability throughout the entire wearing cycle and achieving stable monitoring throughout the entire wearing cycle.
[0041] Specifically, to validate this strategy, the applicant conducted a glucose sensor (CGM) wearing study, in which subjects simultaneously wore sensors of a single standard depth and with two sensing areas: a shallow sensing layer located in the superficial layer and a deep sensing layer located in the deep layer. The CGM concentration readings were then plotted as follows: Figure 10 As shown in the figure, the horizontal axis represents time, and the vertical axis represents the CGM concentration reading. The red line in the figure is the concentration reading of the shallow sensing layer 21 over time, the blue dotted line is the concentration reading of the deep sensing layer 31 over time, and the green line is the concentration reading of the standard depth sensor over time. The "×" in the figure indicates that the analyte parameters measured by collecting finger-prick blood (BGM) during the same period are used as a reference. In the coordinate system, each vertical line from the implantation point (the starting point of the line) represents one day.
[0042] During the same period, analyte parameters measured by collecting finger-prick blood are relatively more accurate. Therefore, the detection accuracy of the sensing layer in CGM can be judged by the detection results of finger-prick blood. The closer the detection results of the sensing layer and finger-prick blood are (reflected in the graph as the lines matching more closely), the more accurate the detection. Conversely, the more the lines in the graph deviate from the detection results of finger-prick blood, the lower the detection accuracy of the sensing layer in CGM. Figure 10 As can be seen, compared with a standard depth sensor, the sensor with two sensing areas exhibits smaller fluctuations and more stable detection signals in the shallow sensing layer 21 (red line in the figure) during the early stages of wear (e.g., within 0-3 days after implantation), and the detection results are more consistent with those obtained from fingertip blood sampling. The deeper sensing layer 31 (blue dotted line in the figure) maintains high accuracy in the later stages of wear (e.g., from the 4th day after implantation) and continues to match the results more closely with fingertip blood sampling. In the later stages of wear, the detection signals of both the shallow sensing layer 21 and the standard depth sensor decrease to varying degrees, and significant deviations begin to appear from the fingertip blood sampling results, with the standard depth sensor showing the largest deviation. Therefore, this application utilizes the temporal complementarity of the shallow sensing layer 21 and the deep sensing layer 31 to significantly improve both signal fluctuation amplitude in the early stages of implantation and signal strength in the later stages, resulting in higher detection accuracy and significantly better overall performance than the standard sensor.
[0043] In the design of implantable analyte sensors, to obtain richer physiological information or achieve multi-parameter mutual calibration, existing technologies employ a scheme where the sensor is configured with two or more working electrodes, each positioned at a different depth within the sensor. This allows for differentiated detection of analyte concentrations in different tissue layers. For example, mutual calibration of two working electrodes at different depths can improve monitoring accuracy. Alternatively, the stability of the sensor's position can be determined by detecting changes in the ratio of the output signals from the two electrodes, and signal compensation can be applied accordingly. However, these approaches treat multiple working electrodes as a signal calibration method, utilizing the positional differences of multiple electrodes at different depths to achieve mutual verification or compensation of signals. They fail to recognize that the intensity and accuracy of the detected signals from multiple electrodes at different depths vary significantly over time.
[0044] Although the above phenomena are widely perceived, the underlying mechanisms and coping strategies have not been fully revealed. This application recognizes that the spatial arrangement of the two electrodes creates complementary characteristics in the temporal dimension, thereby solving a long-standing technical problem in the most direct and effective way.
[0045] As a preferred embodiment, such as Figure 6 , Figure 7 As shown, the sensor is mounted to the transmitting unit 6, which has a bottom surface 631. An implantation segment 126 extends from the bottom surface 631 and is implanted into the host's subcutaneous tissue to acquire analyte parameters. Specifically, as... Figure 6 , Figure 7 As shown, the transmitting unit 6 includes a housing 62 and an electronic module 61 disposed inside the housing 62. The housing 62 is provided with an adhesive part 63, which has a bottom surface 631 (the surface facing the host skin) and is configured to be fixed to the surface of the host skin. A connecting part 11 is disposed inside the housing 62 and is connected to the electronic module 61 (physical connection and / or communication connection). The implantation part 12 has an implantation segment 126 extending from the bottom surface 631 to be implanted under the host skin. The superficial electrode 2, the deep electrode 3, and the superficial sensing layer 21 and the deep sensing layer 31 are all disposed in the implantation segment 126.
[0046] like Figure 6 As shown, in the extension direction of the implantation portion 12, the shallow sensing layer 21 has a first upper edge 211 close to the connecting portion 11, and the distance d1 between the first upper edge 211 and the bottom surface 631 is 1.6mm~2.3mm. A small distance means it is closer to the skin surface, which may cause it to fall off the skin during the wearing process. A large distance may cause it to overlap with the deep sensing layer 31, thus losing the function of coordinating the deep and shallow electrodes.
[0047] like Figure 7As shown, in the extension direction of the implantation portion 12, the deep sensing layer 31 has a second upper edge 311 close to the connecting portion 11, and the distance d2 between the second upper edge 311 and the bottom surface 631 is 2.8mm~4.4mm. If the distance is too small, it is easy to overlap with the shallow sensing layer 21, losing the function of deep and shallow electrodes cooperating. If the distance is too large, it will result in an excessively long implantation portion, which may increase the pain.
[0048] Understandably, after implantation, the bottom surface 631 adheres to the host's skin surface. The distance between the first upper edge 211 and the bottom surface 631 can reflect the position of the upper starting boundary of the shallow sensing layer 21 under the host's skin, and the distance between the second upper edge 311 and the bottom surface 631 can reflect the position of the upper starting boundary of the deep sensing layer 31 under the host's skin.
[0049] The distance between the first upper edge 211 of the superficial sensing layer 21 and the bottom surface 631 is 1.6mm to 2.3mm. The upper starting position of the superficial sensing layer 21 is placed within the reticular layer of the dermis. In the early stage of implantation, this depth has sufficiently avoided the dense capillary clusters in the papillary layer of the dermis, and has not yet entered the distribution area of larger blood vessels in the deep subcutaneous tissue. Therefore, the amount of bleeding caused by puncture is extremely limited. Interfering substances such as red blood cells, thrombin, and proteins in the blood are difficult to climb up the surface of the implantation site 12 to the superficial sensing layer 21 due to the lack of a large amount of blood to carry them. The surface of the superficial sensing layer 21 remains clean and unobstructed by physical shielding. The electron transmission process of the electrode is also not interfered with by blood components. The sensor can establish an accurate and reliable baseline signal from the moment of activation, ensuring the detection accuracy and signal stability in the early stage of implantation.
[0050] The upper starting boundary of the depth sensing layer 31 is located at a depth of 2.8mm to 4.4mm, which has penetrated the dermis. This means that the fibrous encapsulation tissue that migrates downward from the skin surface along the implantation site 12 in the later stages of implantation needs to travel a longer distance to reach the depth sensing layer 31. The encapsulation process is significantly delayed, thereby significantly improving the signal strength in the later stages of implantation.
[0051] Different tissue microenvironments at different depths carry different physiological information. The dermis mainly reflects the local tissue metabolic state, while the deep subcutaneous tissue, being closer to the vascular plexus of the muscle layer, has tissue fluid composition that better represents the metabolic state of the systemic circulatory system. In this application, two electrodes are anchored at two different depths, namely the dermis and the deep subcutaneous tissue, respectively, enabling simultaneous sampling of tissue fluid at different depths. The signal detected by the superficial electrode 2 reflects the local glucose concentration in the dermis, providing a rapid response in the early stages of implantation. The signal detected by the deep electrode 3 reflects the systemic glucose concentration, which is closer to that in the blood, providing stable and reliable monitoring data in the later stages of implantation. The combination of the two allows the sensor to obtain both the rapid response advantage of superficial tissue in the early stages of implantation and the stability and physiological relevance advantage of deep tissue in the later stages of implantation.
[0052] Preferably, d1 is 1.8mm~2.1mm or 1.6mm~2.1mm or 1.8mm~2.3mm or 1.8mm~2mm or 1.9mm~2.1mm. More preferably, d1 can be 1.8mm, 1.9mm, 2mm, 2.1mm or 2.2mm.
[0053] Preferably, d2 is 3mm~4mm or 2.8mm~4mm or 3mm~4.4mm or 3.3mm~3.8mm or 3.5mm~4.2mm. More preferably, d2 can be 2.8mm, 3mm, 3.2mm, 3.5mm, 3.8mm, 4mm or 4.2mm.
[0054] Furthermore, the shallow electrode 2 and the deep electrode 3 may be completely offset in the extension direction of the implantation portion 12, or they may at least partially overlap. Preferably, in the extension direction of the implantation portion 12, the shallow sensing layer 21 and the deep sensing layer 31 are separated from each other, that is, there is a gap between them.
[0055] This application does not limit the arrangement of the shallow electrode 2 and the deep electrode 3, which can be one of the following embodiments: Implementation Method 1: In this implementation method, as follows Figure 5 As shown, the shallow electrode 2 and the deep electrode 3 are located on the same side of the implantation part 12.
[0056] Specifically, the implantation site includes a substrate. A deep electrode and a deep conductive layer are disposed on one side surface of the substrate. A deep insulating layer is disposed outside the deep conductive layer, and a deep sensing layer is disposed on the surface of the deep electrode. A shallow electrode and a shallow conductive layer are disposed on the surface of the deep insulating layer. A shallow insulating layer is disposed outside the shallow conductive layer, and a shallow sensing layer is disposed on the surface of the shallow electrode. Preferably, an outer membrane assembly is further disposed outside the shallow sensing layer and the deep sensing layer, and the outer membrane assembly covers the shallow electrode, the deep electrode, and the shallow and deep sensing layers.
[0057] Implementation Method Two: In this implementation method, as follows Figures 1 to 4 As shown, the shallow electrode 2 is disposed on the first side 121 of the implantation part 12, and the deep electrode 3 is disposed on the second side 122 of the implantation part 12, with the first side 121 and the second side 122 being disposed opposite to each other.
[0058] Specifically, such as Figure 4As shown, the implantation unit 12 includes a substrate 125. A shallow electrode 2 and a shallow conductive layer 24 are disposed on the surface of a first side 121 of the substrate 125. A shallow insulating layer 25 is disposed on the outer side of the shallow conductive layer 24, and a shallow sensing layer 21 is disposed on the surface of the shallow electrode 2. A deep electrode 3 and a deep conductive layer 34 are disposed on the surface of a second side 122 of the substrate 125 opposite to the first side 121. A deep insulating layer 35 is disposed on the outer side of the deep conductive layer 34, and a deep sensing layer 31 is disposed on the surface of the deep electrode 3. An outer membrane assembly is also disposed on the surfaces of the shallow electrode 2 and the deep electrode 3, covering the shallow electrode 2, the deep electrode 3, the shallow sensing layer 21, and the deep sensing layer 31.
[0059] Furthermore, the implantation unit 12 is also provided with a reference electrode 5 and a counter electrode 4, one of which is located on the first side 121 and the other on the second side 122.
[0060] Specifically, in one embodiment, the reference electrode 5 is disposed on the first side 121, which can be inside the shallow electrode 2 (on the side closer to the substrate 125), for example, as... Figure 4 As shown, a reference conductive layer 51 and a reference electrode 5 are disposed on the first side 121 surface of the substrate 125. A reference material 53 (such as Ag or AgCl) is disposed in a local area of the reference conductive layer 51, and a reference insulating layer 52 is disposed on the surface of the reference conductive layer 51. A shallow conductive layer 24 is disposed outside the reference insulating layer 52. Alternatively, the reference electrode 5 may also be located outside the shallow electrode 2 (on the side away from the substrate 125), which is not limited here.
[0061] like Figure 4 As shown, the substrate 125 has a counter electrode conductive layer 41 and a counter electrode 4 on the surface of the deep insulating layer 35. The surface of the counter electrode conductive layer 41 is provided with a counter electrode insulating layer 42, and the counter electrode 4 does not cover the deep electrode 3. The outer membrane assembly covers the counter electrode 4. The reference material 53 and the deep sensing layer 31 are disposed opposite each other on both sides of the implantation portion 12, and the counter electrode 4 and the first sensing area are disposed opposite each other on both sides of the implantation portion 12.
[0062] Preferably, in this application, the conductive layer and the electrode can be solid inert metal materials such as carbon, gold, palladium, and platinum, and the two sensing layers are coated with biological enzymes that can react with the interstitial fluid of the subcutaneous tissue to generate analyte parameters.
[0063] In a preferred embodiment of this implementation, such as Figure 4 As shown, in the extension direction of the implantation portion 12, the shallow electrode 2 and the deep electrode 3 have an overlapping region 26, and the shallow sensing layer 21 and the deep sensing layer 31 are separated from each other.
[0064] A shallow electrode 2 and a deep electrode 3 are respectively disposed on opposite sides of the implantation part 12, with an overlapping area 26 between them in the extending direction of the implantation part 12. Simultaneously, the shallow sensing layer 21 and the deep sensing layer 31 are spaced apart in the extending direction. The overlap of the two electrodes causes the conductive materials on both sides to be stacked rather than laid flat in a certain section of the extending direction of the implantation part 12. Therefore, without changing the length of each electrode, the length of the implantation part 12 is compressed, significantly reducing the puncture trauma suffered by the user during implantation, and improving both the user's wearing experience and the long-term reliability of the sensor. At the same time, the spaced arrangement of the two sensing layers in the extending direction ensures that the two sensing layers are located at different depths under the host skin after implantation, enabling differentiated detection at different depths. The substrate 1 acts as an insulating layer, reliably electrically insulating the electrodes on both sides, eliminating the need for an additional insulating layer as required for electrodes arranged on the same side. Furthermore, the spacing between the two sensing layers can be optimized independently of the amount of electrode overlap.
[0065] Specifically, such as Figure 1 , Figure 3 As shown, the implantation part 12 has a plate-like structure, with the shallow electrode 2 disposed on one side plate surface of the implantation part 12 and the deep electrode 3 disposed on the other side plate surface opposite to that side plate surface.
[0066] It should be noted that in this application, the overlapping area 26 refers to the stacked state in which the deep electrode 3 and the shallow electrode 2 on both sides are electrically isolated but spatially overlapped, that is, the electrodes on both sides are separated by the substrate 1 and electrically insulated from each other.
[0067] In signal transmission of electrochemical sensors, a periodic or pulsed voltage signal is typically applied to the working electrode. As this signal propagates through the electrode, the parasitic capacitance between adjacent electrodes generates coupling current, which is superimposed on the detection signal, forming background noise. When the overlap between two electrodes is too long, the parasitic capacitance increases, and the signal noise also increases.
[0068] As a preferred embodiment of this application, such as Figure 4 As shown, in the extension direction of the implantation part 12, the length L4 of the overlapping area 26 is less than or equal to 0.5 mm. If the overlapping area 26 is too small, it will increase the total length of the implantation part 12, which may increase pain. If the overlapping area 26 is too large, it will reduce the interval between the two sensing areas, affecting the function of the two electrodes and compressing the length of the counter electrode. More preferably, L4 is 0.2 mm to 0.4 mm, 0.2 mm to 0.35 mm, 0.25 mm to 0.4 mm, or 0.25 mm to 0.35 mm. More preferably, L4 can be 0.2 mm, 0.25 mm, 0.28 mm, 0.3 mm, 0.33 mm, 0.35 mm, 0.37 mm, or 0.4 mm.
[0069] In a preferred embodiment, such as Figure 1 , Figure 3 As shown, in the extension direction of the implantation portion 12, the shallow electrode 2 has a first proximal edge 22 and a first distal edge 23, and the shallow sensing layer 21 has a first upper edge 211 near the first proximal edge 22 and a first lower edge 212 near the first distal edge 23; the distance between the first upper edge 211 and the first proximal edge 22 is d3, and the distance between the first lower edge 212 and the first distal edge 23 is d4. The deep electrode 3 has a second proximal edge 32 and a second distal edge 33, and the deep sensing layer 31 has a second upper edge 311 near the second proximal edge 32 and a second lower edge 312 near the second distal edge 33; the distance between the second upper edge 311 and the second proximal edge 32 is d5, and the distance between the second lower edge 312 and the second distal edge 33 is d6.
[0070] The longitudinal relative position between the electrode and the sensing layer determines the starting and ending points of the sensing layer coating on the electrode, directly affecting the effective length of the sensing layer and the mechanical stability of its edges. If the sensing layer extends beyond the edge of the edge electrode, it will result in uneven thickness of the sensing layer, with the edge thickness significantly greater than the central region. This not only affects the uniformity of the enzyme layer on the sensing layer but also makes the edge region of the sensing layer prone to cracking due to stress concentration during implantation. Furthermore, if the sensing layer extends beyond the electrode's coverage area, the electrons generated by the enzyme catalysis reaction in the extended portion cannot be effectively collected due to the lack of conductive pathways, forming an ineffective reaction region and wasting enzyme material.
[0071] This embodiment allows the distance d3 between the upper edge of the shallow sensing layer 21 and the proximal edge of the shallow electrode 2, and the distance d4 between the lower edge of the shallow sensing layer 21 and the distal edge of the shallow electrode 2 to be the same or different (the same applies to the deep sensing layer 31), enabling independent optimization of the position of each sensing layer on the electrode. Taking the shallow sensing layer 21 as an example, when d3 and d4 are the same, the shallow sensing layer 21 is located at the center of the shallow electrode 2 along the length of the implantation portion 12, resulting in the simplest coating process and the easiest achievement of uniform coating. When d3 and d4 are different, the shallow sensing layer 21 is offset relative to the shallow electrode 2 along the length of the implantation portion 12. For example, the shallow sensing layer 21 can be offset towards the distal end of the implantation portion 12 to penetrate deeper under the skin, improving sensitivity in the early stages of implantation, or it can be offset towards the proximal end of the implantation portion 12 to reduce the distance between the shallow sensing layer 21 and the skin surface. At the same time, the increase in d4 can be used to provide a longer exposed electrode not covered by the shallow sensing layer 21 on the side of the shallow sensing layer 21 away from the connecting portion 11, serving as a barrier buffer. The depth sensing layer 31 can also be shifted proximally to ensure that the depth sensing layer 31 is located in a more stable area of the deep electrode 3, so as to avoid the coating peeling off due to the bending and deformation of the distal end of the implant 12 in the subcutaneous fat layer.
[0072] It should be noted that in this embodiment, the measurement directions of d3, d4, d5, and d6 are all along the extension direction of the implantation portion 12. d3 and d5 are the distances between the upper edges of the two sensing layers and the proximal edges of their corresponding electrodes (the side closer to the connecting portion 11 and closer to the skin surface), reflecting the starting position of the upper ends of the two sensing layers. d4 and d6 are the distances between the lower edges of the two sensing layers and the distal edges of their corresponding electrodes (the side closer to the distal end and deeper), reflecting the ending position of the lower ends of the two sensing layers.
[0073] Furthermore, d3, d4, d5, and d6 are 0~1.5mm respectively.
[0074] This application defines d3, d4, d5, and d6 as 0~1.5mm, meaning that the upper and lower edges of the two sensing layers can be inside or flush with the corresponding edges of the electrodes, but not exceeding 1.5mm.
[0075] The sensing layer needs to be drop-coated onto the electrode area to function, so the lower limit of d3, d4, d5, and d6 is at least 0 mm, meaning that the sensing layer is flush with the electrode edge in the extension direction of the implantation portion 12. The upper limit of 1.5 mm ensures that the sensing layer will not have excessively long exposed areas at both ends of the sensing layer due to excessive inward shrinkage. Exposed electrodes are electrochemically active in tissue fluid. Even without an enzyme coating, the conductive material itself will form an electrochemical interface with the tissue fluid, generating a weak background current. When the exposed length exceeds 1.5 mm, this background current may interfere with the purity of the detection.
[0076] More preferably, d3, d4, d5, and d6 are all 0.15mm~1.2mm, 0.2mm~1mm, 0.2mm~1mm, 0.4mm~1mm, or 0.15mm~0.5mm. More preferably, d3, d4, d5, and d6 can be 0.2mm, 0.25mm, 0.3mm, 0.4mm, 0.5mm, 0.8mm, 1mm, 1.1mm, 1.2mm, and 1.5mm, respectively.
[0077] In another preferred embodiment, such as Figure 1 As shown, d4 is greater than d3, meaning the shallow sensing layer 21 is located slightly above the interior of the shallow electrode 2. Preferably, d4 can be 2 to 5 times d3; more preferably, d4 can be 3 to 4.5 times, 2 to 4.5 times, 3 to 5 times, or 3 to 4 times d3; even more preferably, d4 can be 3 times, 3.5 times, 3.8 times, 4 times, 4.2 times, 4.5 times, or 5 times d3.
[0078] Preferably, in the extension direction of the implantation portion 12, the length of the superficial electrode 2 is greater than the length of the deep electrode 3. The superficial electrode 2 being longer than the deep electrode 3 allows the superficial electrode 2 to provide a larger space for positional adjustment of the superficial sensing layer 21, enabling the superficial sensing layer 21 to be flexibly positioned within its electrode range according to individual differences in the various tissue layers of the skin.
[0079] Furthermore, the longer shallow electrode 2, due to its larger longitudinal dimension, has a larger contact area and stronger adhesion with the substrate, providing more stable mechanical support for the shallow sensing layer 21 located above it. This corresponds to the collagen and elastic fibers located in the superficial layer of the skin, preventing edge lifting or peeling under the action of clamping force and friction.
[0080] Specifically, in the extension direction of the implantation portion 12, the length L1 of the superficial electrode 2 and the length L2 of the deep electrode 3 are both set to 0.8mm~4.0mm, so that the sensing layer of each electrode has a sufficient electrochemically active area while the longitudinal dimension is limited within a reasonable physiological window. More preferably, L1 is 2mm~4mm, 2.2mm~4mm, 2mm~3.8mm, 2.7mm~3.2mm, or 2.7mm~3mm; more preferably, L1 can be 2.5mm, 2.7mm, 3mm, 3.2mm, or 3.5mm. More preferably, L2 is 1mm~2.5mm, 1mm~2mm, 1.3mm~2mm, or 1.3mm~1.8mm; more preferably, L2 can be 1.4mm, 1.5mm, 1.6mm, 1.7mm, or 1.8mm.
[0081] In the extending direction of the implantation portion 12, the shallow electrode 2 has a first proximal edge 22 close to the connecting portion 11, and the deep electrode 3 has a second distal edge 33 away from the connecting portion 11, such as... Figure 1 , Figure 3 , Figure 4 As shown, the distance L3 between the first proximal edge 22 and the second distal edge 33 is 1.1mm~4.0mm, which allows the two working electrodes to be in two different positions, deep and shallow, respectively, and also ensures that the overall implanted part will not easily increase the wearing pain due to the increase in size.
[0082] More preferably, L3 is 2 mm to 4 mm, 2.2 mm to 4 mm, 2 mm to 3.8 mm, or 3 mm to 4 mm. More preferably, L3 can be 2 mm, 2.2 mm, 3 mm, 3.5 mm, 3.8 mm, or 4 mm.
[0083] Preferably, the shallow sensing layer 21 and / or the deep sensing layer 31 have different thicknesses along the length of the substrate 1, wherein the thickness near the end of the connecting portion 11 is greater than the thickness near the distal end of the implantation portion 12.
[0084] Because the oxygen partial pressure is higher in the area near the skin surface, the thicker enzyme layer makes full use of the high oxygen environment to generate a strong signal. The oxygen partial pressure is lower in the distant area away from the skin surface, and the thinner enzyme layer avoids incomplete reactions and accumulation of intermediate products due to insufficient oxygen supply. This makes the enzyme reaction rates of the two sensing layers at different depths tend to match, improving the sensitivity uniformity of the sensor across the entire sensing layer.
[0085] As a preferred option, such as Figure 1 As shown, the angle α2 between the implant 12 and the skin surface (considering the skin surface as a plane) is 45°~135°, meaning it can be implanted under the skin perpendicular to the skin surface or at an angle to the skin surface. More preferably, α2 is 50°~90° or 50°~100° or 45°~90°, and even more preferably, α2 is 90°. Implanting at 90° perpendicular to the skin surface reduces the probability of implantation failure.
[0086] In a preferred embodiment, such as Figure 2 As shown, the implantation part 12 includes a receiving section 123 and a guide section 124 extending from the receiving section 123. The shallow electrode 2 and the deep electrode 3 are disposed on the receiving section 123. The front view of the guide section 124 is trapezoidal. The trapezoid includes a lower base 1242 close to the receiving section 123 and an upper base 1241 away from the receiving section 123. The length of the upper base 1241 is less than the length of the lower base 1242.
[0087] like Figure 8 , Figure 9 As shown, when implanting the segment 126 under the host's skin, a puncture needle 7 is required. Specifically, the puncture needle 7 forms a cavity 71, and the segment 126 is located in the cavity 71. The end of the puncture needle 7 is provided with a beveled surface 72 to form a tip structure.
[0088] Because the implantable segment 126 in this application is longer than the subcutaneous portion of existing sensors, the possibility of the implantable segment 126 being exposed from the cavity 71 of the puncture needle 7 increases during the implantation of the implantable segment 126 into the host's subcutaneous tissue using the puncture needle 7. Once the implantable segment 126 is exposed from the puncture needle 7, the exposed tip of the implantable segment 126 will directly contact the tissue and bear the shear force and friction between the implantable segment 126 and the subcutaneous tissue during the puncture process. This may not only cause the sensing layer to be scraped off and enzyme molecules to be damaged, but may also cause the end of the implantable segment 126 to be bent or broken, ultimately causing the sensor to fail before implantation. Furthermore, after implantation, the longer implant segment 126 may penetrate the host's dermis and enter the subcutaneous tissue layer. When the host wears the sensor and moves or adjusts their posture, the sharp edges at the end of the implant segment 126 may cause severe scratching with the tissue in the subcutaneous tissue layer or poke the surrounding tissue, thereby causing pain or local inflammation. This not only increases the user's wearing experience, but the local inflammation may also accelerate the process of fiber encapsulation, causing the fiber encapsulation to reach the sensing layer earlier and have an impact, resulting in a reduction in the lifespan of the sensor.
[0089] Therefore, in this application, a beveled end face is provided at the distal end of the substrate 1, making the shape of the distal end more similar to the shape of the tip of the puncture needle 7, so that the implanted segment 126 can be completely accommodated within the cavity 71 of the puncture needle 7 without being exposed. The cavity 71 formed by the puncture needle 7 provides physical protection for the implanted segment 126. Throughout the entire process of the puncture needle 7 penetrating the epidermis and dermis, the implanted segment 126 is completely accommodated within the cavity 71 and does not directly contact the tissue. Therefore, the sensing layer is not directly subjected to shearing, friction, or extrusion forces during the puncture process. This avoids coating peeling, scratch damage, or enzyme molecule shedding that may occur when the sensing layer penetrates dense dermal tissue, and also prevents the substrate 1 from bending or breaking due to direct puncture resistance. Meanwhile, the trapezoidal design also allows the guide segment 124 to play a guiding role during the implantation process, enabling the longer implantation segment 126 to be inserted more smoothly into the subcutaneous tissue, reducing the resistance encountered by the implantation segment 126 during the implantation process, and helping to place each electrode, especially the deep electrode 3, in the ideal depth area.
[0090] Furthermore, since the front view of the guide segment 124 is trapezoidal, its shape is more rounded compared to a triangle (which forms a pointed structure). This avoids the formation of sharp edges or points at the distal end of the substrate 1. During the sensor retention stage after the puncture needle 7 is withdrawn, even if the guide segment 124 comes into contact with the surrounding tissue, the trapezoidal structure has a smaller cutting effect on the tissue, reducing pain and micro-damage caused by local tissue scraping or puncture.
[0091] Preferably, such as Figure 2As shown, the angle α1 between the hypotenuse of the trapezoid and the upper base 1241 is 52°~72°, 55°~70°, 55°~62°, 52°~62°, 55°~65°, or 60°~70°. Forming a certain angle at the distal end can reduce the probability of the sensor dislodging from the puncture needle 7. More preferably, α1 can be 58°, 60°, 61°, 62°, 63°, or 65°.
[0092] Furthermore, such as Figure 8 , Figure 9 As shown, in the extending direction of the puncture needle 7, the beveled surface 72 has a beveled end 722 near the needle hub and a needle tip 721 away from the needle hub (also near the needle tip). The upper base 1241 is closer to the connecting portion 11 than the beveled end 722, and the distance d8 between the upper base 1241 and the beveled end 722 is no greater than 2 mm. More preferably, d8 is no greater than 1.8 mm, 1.5 mm, 1.3 mm, 1.1 mm, or 1 mm. More preferably, d8 can be 1 mm, 1.2 mm, 1.3 mm, or 1.5 mm.
[0093] Preferably, the deep electrode 3 can extend to the distal end of the implantation portion 12, and an isolation region can be provided between the second distal edge 33 of the deep electrode 3 away from the connection portion 11 and the end of the implantation segment 126.
[0094] When the isolation area is present, the deep electrode 3 is prevented from being directly exposed to the force-bearing area at the very tip of the puncture site. Since the end of the implanted segment 126 (the end furthest from the connector 11) experiences the greatest frictional force when crossing tissue, the isolation area effectively provides a protected segment for the deep electrode 3, allowing the dominant force of the puncture to be borne by the distal end and the isolation area rather than the deep electrode 3 itself. Simultaneously, the isolation area acts as a blood buffer for the deep sensing layer 31 during the initial implantation phase. Blood seeping from the distal puncture wound first reaches the isolation area, which is not covered by biological enzymes. Partial dissipation of blood in this area provides additional protection for the deep sensing layer 31, requiring blood to cross the isolation area before reaching it. During this process, some blood is absorbed by surrounding tissue and some coagulates, significantly reducing the amount of blood reaching the deep sensing layer 31.
[0095] Furthermore, such as Figure 3 As shown, the distance d7 between the second distal edge 33 and the end of the implanted segment 126 is no greater than 1.2 mm. In the process of covering the sensor with an outer membrane, a thicker outer membrane tends to be deposited at the distal end. Therefore, to ensure uniform outer membrane thickness at the working electrode surface, a buffer area is added between the second distal edge 33 and the end of the implanted portion 12. More preferably, d7 is no greater than 1 mm, 0.8 mm, 0.7 mm, or 0.5 mm. Even more preferably, d7 can be 0.4 mm, 0.5 mm, 0.6 mm, 0.7 mm, or 0.8 mm.
[0096] Preferably, in the extension direction of the implantation portion 12, the length of the receiving segment 123 is greater than the length of the guiding segment 124.
[0097] Preferably, the second distal edge 33 is flush with the lower edge of the receiving section 123. In this case, the length d7 of the isolation area is the length of the guide section 124.
[0098] In existing technologies, different electrodes in analyte sensors typically employ different catalytic mechanisms. Taking blood glucose monitoring as an example, first-generation technology relies on natural oxygen as an electron mediator, applying a high voltage of approximately +0.6V (vs. reference electrode) to the working electrode to oxidize H₂O₂ and generate current. Second-generation technology relies on electron mediators to transfer electrons, applying a low voltage of approximately +0V to +0.3V (vs. reference electrode) to the working electrode to directly oxidize the reduced mediator, releasing electrons and generating current. The use of different catalytic mechanisms for multiple electrodes leads to complex processes and significant performance differences. Furthermore, when two working electrodes employ different catalytic mechanisms, their respective interference characteristics differ, requiring complex weighted corrections during signal fusion, and the correction model struggles to adapt to variations in interfering substance concentrations across different individuals.
[0099] Therefore, as a preferred embodiment of this application, the shallow sensing layer 21 and the deep sensing layer 31 include glucose oxidase and an electron mediator, the electron mediator being configured to transfer electrons generated by the reaction of glucose oxidase with the host's interstitial fluid to the shallow conductive layer and the deep conductive layer.
[0100] This application incorporates glucose oxidase and an electron mediator in both the shallow sensing layer 21 and the deep sensing layer 31. The artificial electron mediator is configured to transfer electrons generated by glucose oxidase catalyzing glucose to the corresponding conductive layer, meaning both sensing layers employ second-generation technology. This allows the two sensing layers to be fabricated using identical material systems and coating processes, significantly reducing manufacturing complexity and batch-to-batch variability.
[0101] In human skin, there is a significant physiological gradient of oxygen partial pressure along the depth direction. The oxygen partial pressure is relatively high in the dermis and gradually decreases with increasing depth. Upon entering the subcutaneous fat layer, the oxygen partial pressure decreases further because the blood supply to the fat tissue is far less abundant than that of the dermis. If the two sensing layers use a first-generation technology, the superficial sensing layer 21 will have a higher response efficiency due to its ample oxygen supply, while the deep sensing layer 31 will have a limited response efficiency due to its lower oxygen partial pressure. This difference in response caused by the oxygen gradient does not stem from a real difference in glucose concentration, but rather is a systematic bias superimposed on the detection signal, which will seriously affect the accuracy of calibration and fusion of the superficial and deep signals.
[0102] In this application, both sensing layers utilize electron mediators instead of oxygen as the electron transport medium, thus freeing the enzyme reaction rates of both sensing layers from the limitations imposed by local oxygen partial pressure. Regardless of whether the two sensing layers are located in a high-oxygen or low-oxygen environment, the electrons generated by the glucose oxidase-catalyzed reaction are transferred to the conductive layer through the mediator with almost identical efficiency. This ensures that the signal differences measured by the two sensing layers primarily reflect the true differences in glucose concentration, rather than inherent biases of the electrochemical system. Consequently, the signals from the two sensing layers exhibit higher consistency, leading to higher accuracy through mutual calibration and fusion algorithms based on the two signals.
[0103] Furthermore, both sensing layers in this application contain glucose oxidase and electron mediators, ensuring complete uniformity in their catalytic mechanisms. Both layers transfer electrons generated by glucose oxidase catalysis to the conductive layer via electron mediators. The two sensing layers share identical catalytic reaction pathways and electron transfer mechanisms. Their responses depend solely on glucose concentration and their respective enzyme loading, rather than on the oxygen supply of the environment, thus reducing oxygen from a confounding variable to an irrelevant one. Moreover, both sensing layers exhibit the same temperature sensitivity and the same long-term drift trend. The sensitivity decay rates of the two GOx electrodes in vivo are similar, ensuring the relative relationship between the two signals remains stable throughout the entire wearing cycle. This facilitates the calibration of the sensitivity of the other electrode using one electrode without considering differences in aging rates between different enzymes.
[0104] In this application, the electron mediator refers to a non-biological small molecule compound that replaces natural oxygen as an electron acceptor in the glucose oxidase catalytic reaction. It can accept electrons from the reduced glucose oxidase and then diffuse or transfer them through the molecular chain to the surface of the conductive layer to complete the electron transfer.
[0105] Of course, in other embodiments, both sensing layers may also contain glucose dehydrogenase and electron mediator, or one of them may contain glucose oxidase and electron mediator, and the other may contain glucose dehydrogenase and electron mediator; this is not limited here.
[0106] Preferably, the surface of the implantation portion 12 is provided with an outer membrane assembly, which covers the shallow electrode 2 and the deep electrode 3; the outer membrane assembly includes at least one outer membrane.
[0107] Further, as a preferred embodiment, a first outer membrane and a second outer membrane located outside the first outer membrane, the second outer membrane comprising a negatively charged polymer material. The first outer membrane covers the outer surfaces of the shallow sensing layer 21 and the deep sensing layer 31, controlling the diffusion rate of glucose and providing mechanical protection and a biocompatible interface for the two sensing layers. The second outer membrane covers at least a portion of the outer surface of the first outer membrane, and the second outer membrane comprises a negatively charged polymer material. Human tissue fluid contains various electrochemically active exogenous interfering substances, such as ascorbic acid, uric acid, and acetaminophen. These molecules typically exist in tissues in a negatively charged form (e.g., ascorbate ions, urate ions). Driven by a concentration gradient, these interfering molecules spontaneously diffuse into the sensor, undergoing oxidation reactions on the electrode surface to generate non-glucose-dependent current signals, leading to falsely high blood glucose readings.
[0108] In this application, the negatively charged polymer material contained in the second outer membrane has a high negative charge density. When negatively charged interfering molecules attempt to diffuse from the tissue fluid into the sensor, they must first pass through the outermost second outer membrane. Since the second outer membrane and the interfering molecules carry the same charge (both are negative), an electrostatic repulsion occurs between them, causing the interfering molecules to be bounced back or significantly slowed down on the surface of the second outer membrane, preventing them from effectively penetrating this layer to reach the inner sensing layer. Simultaneously, the sulfonic acid groups in the negatively charged polymer material endow this layer with good hydrophilicity and biocompatibility, allowing the sensor to be quickly wetted by the tissue fluid after implantation, reducing the initial signal delay caused by the hydrophobicity of the outer membrane.
[0109] Preferably, the thickness of the second outer membrane is 0.5~10μm, more preferably 1~5μm, even more preferably 1~3μm, 2~5μm, or 1~4μm, and most preferably 3μm or 3.5μm. Within this thickness range, the sensor can maintain high sensitivity and fast response while effectively repelling interfering substances through electrostatic repulsion, achieving the best balance between sensitivity and anti-interference performance. Furthermore, the negatively charged polymer material can form a three-dimensional interpenetrating network structure through chemical cross-linking, enhancing the structural stability of the second outer membrane in the body fluid environment. By adding a cross-linking agent (such as polyethylene glycol diglycidyl ether), a three-dimensional interpenetrating network is formed during film formation, effectively suppressing volume changes caused by swelling, enhancing the stability of the outer membrane in body fluids, and ensuring that the sensor continuously possesses anti-interference capabilities during the wearing period. The position of the negatively charged polymer layer in the multilayer outer membrane also affects its anti-interference performance. With the negatively charged polymer layer located on the outermost layer of the sensor, interfering molecules are blocked by electrostatic repulsion before they come into contact with any internal functional layers, resulting in the highest protection efficiency. Therefore, this application places the second outer membrane on the outside of the first outer membrane (i.e., the side away from the sensing layer), so that the second outer membrane becomes the first line of defense that the interfering molecules must face before reaching the sensing layer, making full use of the electrostatic repulsion mechanism to intercept the interfering substances at the source.
[0110] In another embodiment, the outer membrane assembly comprises only one outer membrane, i.e., only the first outer membrane in the above embodiments is used.
[0111] Preferably, the analyte sensor of this application can be monitored using the following method to improve accuracy throughout the entire wearing period. This includes acquiring the host's first vital sign parameter through the shallow sensing layer 21; acquiring the host's second vital sign parameter through the deep sensing layer 31; obtaining the host's analyte concentration based on the first vital sign parameter during a first time period after implantation; and obtaining the host's analyte concentration based on the second vital sign parameter during a second time period after the first time period; wherein both the first and second vital sign parameters are used to characterize the host's glucose concentration.
[0112] The two sensing layers are located at different depths during implantation, and their detection accuracy is complementary over time. The sensor faces signal attenuation during both the initial bleeding phase and the later encapsulation phase, but the timing and degree of attenuation differ. Specifically, the superficial sensing layer, due to its shallower implantation, has a high density of capillaries in the dermis, but the capillaries are small in diameter, resulting in relatively less bleeding in the initial implantation phase. However, in the later implantation phase, as the encapsulating tissue grows downwards from the skin surface along the implantation site 12, it first covers the superficial sensing layer, causing signal attenuation. Conversely, the deeper sensing layer, due to its deeper implantation, experiences greater bleeding and severity in the initial puncture damage to larger vessels in the subcutaneous fat layer. However, the encapsulating tissue requires a longer migration distance to reach the deeper sensing layer, thus maintaining better signal strength in the later implantation phase, while exhibiting greater error in the initial implantation phase.
[0113] This application utilizes the complementary nature of this time dimension to obtain the host's analyte concentration based on the first vital sign parameters obtained by the shallow sensing layer 21 during the first time period after implantation, and to obtain the host's analyte concentration based on the second vital sign parameters obtained by the deep sensing layer 31 during the second time period after the first time period. For example, after implantation, during the first 0-3 days of analyte sensor activation, the glucose concentration measured by the shallow sensing layer 21 is used as the glucose concentration output by the sensor; from the 4th day (inclusive) onwards, the glucose concentration measured by the deep sensing layer 31 is used as the glucose concentration output by the sensor.
[0114] In this application, taking the first time period as an example, the concentration of the analyte in the host can be determined in one of the following embodiments: Example 1: During the first time period, the first vital sign parameter is used as the sole signal source and directly converted or calculated as the analyte concentration. In this case, the second vital sign parameter is not used for the calculation of the analyte concentration.
[0115] Example 2: The first vital sign parameter is the primary indicator, and the second vital sign parameter is the secondary indicator. The second vital sign parameter is used as background reference, baseline calibration or anomaly judgment auxiliary information, but the final determination of the analyte concentration is still mainly determined by the first vital sign parameter.
[0116] Example 3: Different weighting coefficients were assigned to the first vital sign parameter and the second vital sign parameter, with the weighting coefficient of the first vital sign parameter being greater than that of the second vital sign parameter. The weighted result of the two was used as the analyte concentration.
[0117] In all three embodiments described above, the first vital sign parameter constitutes the main contributing source of analyte concentration information within that time period.
[0118] Similarly, in the second time period, using the second vital sign parameter as the basic source for obtaining analyte concentrations also includes three scenarios: First, using the second vital sign parameter as the sole signal source. Second, using the second vital sign parameter as the primary source and the first vital sign parameter as a secondary source. Third, assigning weights to the two vital sign parameters, with the weight coefficient of the second vital sign parameter being greater than that of the first vital sign parameter.
[0119] For any parts not mentioned in this application, existing technologies may be used or referenced.
[0120] The various embodiments in this specification are described in a progressive manner. The same or similar parts between the various embodiments can be referred to each other. Each embodiment focuses on describing the differences from other embodiments.
[0121] The above description is merely an embodiment of this application and is not intended to limit the scope of this application. Various modifications and variations can be made to this application by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of this application should be included within the scope of the claims of this application.
Claims
1. A miniature biosensor for continuous analyte monitoring, characterized in that, include: A substrate having a connecting portion and an implantation portion, the connecting portion being located outside the host body and configured for connection to an electronic module, the implantation portion being connected to the connecting portion, the implantation portion having an implantation segment configured for implantation into subcutaneous tissue of the host to obtain analyte parameters; A shallow electrode is disposed in the implantation segment, and a shallow sensing layer is disposed on the surface of the shallow electrode, the shallow sensing layer covering at least a portion of the shallow electrode. The shallow electrode is configured to: obtain the concentration of the analyte based on a first vital sign parameter acquired by the shallow sensing layer during a first time period after implantation. and A deep electrode is disposed in the implantation segment, and a deep sensing layer is disposed on the surface of the deep electrode, the deep sensing layer covering at least a portion of the deep electrode. The deep electrode is configured to: obtain the analyte concentration based on a second vital sign parameter acquired by the deep sensing layer during a second time period following a first time period. Wherein, in the extension direction of the implanted part, the length of the implanted segment is 5.5mm~7.5mm, and the shallow electrode is closer to the connection part than the deep electrode; the first vital sign parameter and the second vital sign parameter are both used to characterize the host's glucose concentration.
2. The miniature biosensor for continuous analyte monitoring according to claim 1, characterized in that, The sensor is used to be mounted to the transmitting unit, which has a bottom surface. The implant segment extends from the bottom surface and is implanted into the host subcutaneous tissue to obtain analyte parameters. In the extension direction of the implant, the shallow sensing layer has a first upper edge near the connecting portion. The distance between the first upper edge and the bottom surface is d1, where d1 is 1.6 mm to 2.3 mm.
3. The miniature biosensor for continuous analyte monitoring according to claim 1 or 2, characterized in that, The sensor is used to be mounted to the transmitting unit, which has a bottom surface. The implant segment extends from the bottom surface and is implanted into the host subcutaneous tissue to obtain analyte parameters. In the extension direction of the implant, the depth sensing layer has a second upper edge near the connecting portion. The distance between the second upper edge and the bottom surface is d2, where d2 is 2.8 mm to 4.4 mm.
4. The miniature biosensor for continuous analyte monitoring according to claim 1, characterized in that, The implantation segment includes a receiving segment and a guiding segment extending from the receiving segment. The receiving segment is closer to the connection portion than the guiding segment. The shallow electrode and the deep electrode are disposed in the receiving segment. The front view of the guiding segment is trapezoidal. The trapezoid includes a lower base close to the receiving segment and an upper base away from the receiving segment. The length of the upper base is less than the length of the lower base.
5. The miniature biosensor for continuous analyte monitoring according to claim 4, characterized in that, The angle between the hypotenuse and the upper base of the trapezoid is 52° to 72°.
6. The miniature biosensor for continuous analyte monitoring according to claim 1, characterized in that, The shallow electrode and the deep electrode are located on the same side of the implanted segment.
7. The miniature biosensor for continuous analyte monitoring according to claim 1, characterized in that, The shallow electrode is disposed on the first side of the implantation segment, and the deep electrode is disposed on the second side of the implantation segment, with the first side and the second side being disposed opposite to each other.
8. The miniature biosensor for continuous analyte monitoring according to claim 7, characterized in that, In the extension direction of the implanted portion, the shallow electrode and the deep electrode have an overlapping area, and the shallow sensing layer and the deep sensing layer are separated.
9. The miniature biosensor for continuous analyte monitoring according to claim 8, characterized in that, In the direction of extension of the implanted portion, the length of the overlapping area is less than or equal to 0.5 mm.
10. The miniature biosensor for continuous analyte monitoring according to claim 1, characterized in that, In the extension direction of the implantation portion, the shallow electrode has a first proximal edge and a first distal edge, and the shallow sensing layer has a first upper edge near the first proximal edge and a first lower edge near the first distal edge; the distance between the first upper edge and the first proximal edge is d3, and the distance between the first lower edge and the first distal edge is d4. In the extension direction of the implantation portion, the deep electrode has a second proximal edge and a second distal edge, and the deep sensing layer has a second upper edge near the second proximal edge and a second lower edge near the second distal edge; the distance between the second upper edge and the second proximal edge is d5, and the distance between the second lower edge and the second distal edge is d6, wherein d3, d4, d5, and d6 are all 0-1.5 mm.
11. The miniature biosensor for continuous analyte monitoring according to claim 1, characterized in that, In the extension direction of the implanted portion, the deep electrode has a second distal edge away from the connecting portion, and the distance between the second distal edge and the end of the implanted segment is 0-1.2 mm.
12. The miniature biosensor for continuous analyte monitoring according to claim 1, characterized in that, In the extension direction of the implanted portion, the length of the shallow electrode is greater than the length of the deep electrode.
13. The miniature biosensor for continuous analyte monitoring according to claim 1, characterized in that, In the extension direction of the implanted portion, the lengths of both the shallow electrode and the deep electrode are set to 0.8 mm to 4.0 mm.
14. The miniature biosensor for continuous analyte monitoring according to claim 1 or 13, characterized in that, In the extension direction of the implanted portion, the shallow electrode has a first proximal edge close to the connecting portion, and the deep electrode has a second distal edge away from the connecting portion, the distance between the first proximal edge and the second distal edge being 1.1mm-4.0mm.
15. The miniature biosensor for continuous analyte monitoring according to claim 1, characterized in that, The shallow sensing layer and the deep sensing layer contain glucose oxidase and an electron mediator configured to transfer electrons generated by the reaction of the glucose oxidase with the host interstitial fluid to the conductive layer.
16. The miniature biosensor for continuous analyte monitoring according to claim 1, characterized in that, The implant segment has an outer membrane assembly on its surface, which covers the shallow electrode and the deep electrode; the outer membrane assembly includes a first outer membrane and a second outer membrane disposed outside the first outer membrane, the second outer membrane comprising a negatively charged polymer material.
17. A method for monitoring host vital signs parameters, characterized in that, The method, using the sensor according to any one of claims 1-16, comprises: The host's first vital signs parameters are obtained through the shallow sensing layer; The host's second vital signs parameters are obtained through the depth sensing layer; During the first time period after implantation, the host's analyte concentration is obtained based on the first vital sign parameter; During a second time period following the first time period, the analyte concentration of the host is obtained based on the second vital sign parameter.
Citation Information
Patent Citations
Analyte sensor with extended lifetime
CN113038875A
